Search Results

Containing any of the words

Only of the type

A Phase 3, single-arm, multicenter, multinational, open label,one-way crossover study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged ≥ 12 years with severe hemophilia A or B, with or without inhibitory antibodies to factor VIII or IX Drug Clinical Trial

Roles and Responsibilities of Regulatory Bodies in Evaluating & Monitoring of Vaccine Safety: Focusing on COVID-19 Vaccines Workshop

"A multicenter, multinational, prospective, interventional,single-arm, Phase IV study evaluating the clinicalefficacy and safety of 26 weeks of treatment with insulin glargine 300 U/mL (Gla-300) in patients with Type 2 diabetes mellitus uncontrolled on basal insulin" Drug Clinical Trial

A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705 Drug Clinical Trial

The ENERGY 3 Study: A Randomized, Controlled, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Children with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency Drug Clinical Trial

The ENERGY 2 Study: An Open-Label Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Infants with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency Drug Clinical Trial

"Study H9X-MC-GBGC is a Phase 3, randomized, double-blind, placebo-controlled trial withan open-label extension that investigates the effect of the addition of dulaglutide (0.75 and1.5 mg/week) or placebo weekly to metformin and/or basal insulin on change from baselinein hemoglobin A1c at 26 weeks in children and adolescents with type 2 diabetes mellitus" Drug Clinical Trial

"Study H9X-MC-GBGC is a Phase 3, randomized, double-blind, placebo-controlled trial with an open-label extension that investigates the effect of the addition of dulaglutide (0.75 and 1.5 mg/week) or placebo weekly to metformin and/or basal insulin on change from baseline in hemoglobin A1c at 26 weeks in children and adolescents with type 2 diabetes mellitus" Drug Clinical Trial

SFDA Alerts : ‘ VICTOZA’ drug should only be used under prescription and for Type 2 –Diabetic patients Warnings

The SFDA Will Sponsor One of The Panel Discussions:The 4th Conference on Food and Nutrition Takes Place Next Sunday News